LIMINAL BIOSCIENCES INC (LMNL)
CA53272L2021 - Common Stock
LMNL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. LMNL has a bad profitability rating. Also its financial health evaluation is rather negative. LMNL has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year LMNL was profitable.
LMNL had a negative operating cash flow in the past year.
In multiple years LMNL reported negative net income over the last 5 years.
In the past 5 years LMNL always reported negative operating cash flow.
1.2 Ratios
LMNL has a Return On Assets of 1.46%. This is amongst the best in the industry. LMNL outperforms 93.73% of its industry peers.
The Return On Equity of LMNL (2.16%) is better than 93.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.46% | ||
| ROE | 2.16% | ||
| ROIC | N/A |
ROA(3y)-29.63%
ROA(5y)-80.67%
ROE(3y)-159.64%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of LMNL (94.11%) is better than 99.67% of its industry peers.
LMNL does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 94.11% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
LMNL does not have a ROIC to compare to the WACC, probably because it is not profitable.
LMNL has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for LMNL has been increased compared to 5 years ago.
The debt/assets ratio for LMNL has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -45.25, we must say that LMNL is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -45.25, LMNL is not doing good in the industry: 95.71% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.02 indicates that LMNL is not too dependend on debt financing.
The Debt to Equity ratio of LMNL (0.02) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -45.25 |
ROIC/WACCN/A
WACC7.87%
2.3 Liquidity
LMNL has a Current Ratio of 2.78. This indicates that LMNL is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of LMNL (2.78) is worse than 74.75% of its industry peers.
LMNL has a Quick Ratio of 2.78. This indicates that LMNL is financially healthy and has no problem in meeting its short term obligations.
LMNL has a worse Quick ratio (2.78) than 72.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.78 | ||
| Quick Ratio | 2.78 |
3. Growth
3.1 Past
LMNL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -99.10%.
Looking at the last year, LMNL shows a very negative growth in Revenue. The Revenue has decreased by -12.92% in the last year.
Measured over the past years, LMNL shows a very negative growth in Revenue. The Revenue has been decreasing by -59.99% on average per year.
EPS 1Y (TTM)-99.1%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-53.93%
Revenue 1Y (TTM)-12.92%
Revenue growth 3Y-56.58%
Revenue growth 5Y-59.99%
Revenue growth Q2Q-28.66%
3.2 Future
Based on estimates for the next years, LMNL will show a very negative growth in Earnings Per Share. The EPS will decrease by -230.98% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-907.27%
EPS Next 2Y-230.98%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 77.27, the valuation of LMNL can be described as expensive.
Based on the Price/Earnings ratio, LMNL is valued cheaply inside the industry as 93.89% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of LMNL to the average of the S&P500 Index (28.06), we can say LMNL is valued expensively.
LMNL is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 77.27 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
LMNL's earnings are expected to decrease with -230.98% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-230.98%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for LMNL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
LIMINAL BIOSCIENCES INC
NASDAQ:LMNL (9/25/2023, 7:00:18 PM)
8.5
+0.01 (+0.12%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap19.82M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 77.27 | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.46% | ||
| ROE | 2.16% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | 94.11% | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.78 | ||
| Quick Ratio | 2.78 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-99.1%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-907.27%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-12.92%
Revenue growth 3Y-56.58%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y